{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:01:17Z","timestamp":1790136077271,"version":"4.0.1"},"reference-count":83,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2022,6,3]]},"DOI":"10.1080\/17512433.2022.2100346","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T09:52:59Z","timestamp":1657878779000},"page":"671-688","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5987-068X","authenticated-orcid":false,"given":"Silvia","family":"G\u00f3mez-Zorrilla","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain"},{"name":"Infectious Pathology and Antimicrobals Research group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Barcelona, Spain"},{"name":"Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra, Barcelona, Spain"},{"name":"Center for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4374-2173","authenticated-orcid":false,"given":"Elena","family":"Sendra","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain"},{"name":"Infectious Pathology and Antimicrobals Research group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-5459","authenticated-orcid":false,"given":"Juan P.","family":"Horcajada","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain"},{"name":"Infectious Pathology and Antimicrobals Research group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Barcelona, Spain"},{"name":"Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra, Barcelona, Spain"},{"name":"Center for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"issue":"21","key":"e_1_3_5_3_1","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1001\/jama.294.21.2712","article-title":"Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002","volume":"294","author":"Fry AM","year":"2005","unstructured":"Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA. 2005;294(21):2712\u20132719.","journal-title":"JAMA"},{"key":"e_1_3_5_4_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte T","year":"2012","unstructured":"Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71\u201379.","journal-title":"Thorax"},{"issue":"8","key":"e_1_3_5_5_1","doi-asserted-by":"crossref","first-page":"e71375","DOI":"10.1371\/journal.pone.0071375","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Czech Republic, Hungary, Poland and Slovakia","volume":"8","author":"Tichopad A","year":"2013","unstructured":"Tichopad A, Roberts C, Gembula I, et al. Clinical and economic burden of community-acquired pneumonia among adults in Czech Republic, Hungary, Poland and Slovakia. PLOS ONE. 2013;8(8):e71375.","journal-title":"PLOS ONE"},{"key":"e_1_3_5_6_1","unstructured":"World Health Organization. Global Health Estimates; 2019 [cited 2021 Dec 12]. Available from: https:\/\/www.who.int\/gard\/publications\/The_Global_Impact_of_Respiratory_Disease.pdf"},{"issue":"10258","key":"e_1_3_5_7_1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"2019 diseases and injuries collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"GBD","year":"2020","unstructured":"GBD. 2019 diseases and injuries collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204\u20131222.","journal-title":"Lancet"},{"key":"e_1_3_5_8_1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"CDC EPIC study team. Community- acquired pneumonia requiring hospitalization among U.S","volume":"373","author":"Jain S","year":"2015","unstructured":"Jain S, Self WH, Wunderink RG, et al. CDC EPIC study team. Community- acquired pneumonia requiring hospitalization among U.S. Adults. N Engl J Med. 2015;373:415\u2013427.","journal-title":"Adults. N Engl J Med"},{"issue":"8","key":"e_1_3_5_9_1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10096-020-03870-3","article-title":"Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study","volume":"39","author":"Carugati M","year":"2020","unstructured":"Carugati M, Aliberti S, Sotgiu G, et al., Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. Eur J Clin Microbiol Infect Dis. 39(8): 1513\u20131525. 2020.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"e_1_3_5_10_1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1164\/rccm.200603-350OC","article-title":"Community-Acquired Pneumonia Organization (CAPO) investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia","volume":"175","author":"Arnold FW","year":"2007","unstructured":"Arnold FW, Summersgill JT, Lajoie AS, et al. Community-Acquired Pneumonia Organization (CAPO) investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175(10):1086\u20131093.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"e_1_3_5_11_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/648678","article-title":"Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods","volume":"50","author":"Johansson N","year":"2010","unstructured":"Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50(2):202\u2013209.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_12_1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200103013440908","article-title":"Aspiration pneumonitis and aspiration pneumonia","volume":"344","author":"Marik PE","year":"2001","unstructured":"Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001;344:665\u2013671.","journal-title":"N Engl J Med"},{"issue":"7","key":"e_1_3_5_13_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1056\/NEJMra1714562","article-title":"Aspiration pneumonia","volume":"380","author":"Mandell LA","year":"2019","unstructured":"Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med. 2019 14;380(7):651\u2013663.","journal-title":"N Engl J Med"},{"key":"e_1_3_5_14_1","unstructured":"WHO. Coronavirus Disease. (COVID-2019) Situation report. Geneva; 2021 [cited 2021 Dec 12]. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports"},{"issue":"6","key":"e_1_3_5_15_1","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1183\/09031936.05.00055705","article-title":"European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections","volume":"26","author":"Woodhead M","year":"2005","unstructured":"Woodhead M, Blasi F, Ewig S, et al., European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26(6):1138\u20131180.","journal-title":"Eur Respir J"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST"},{"issue":"2","key":"e_1_3_5_17_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/archpedi.1979.02130020079017","article-title":"Penicillin-insensitive pneumococci. Case report and review","volume":"133","author":"Ahronheim GA","year":"1979","unstructured":"Ahronheim GA, Reich B, Marks MI. Penicillin-insensitive pneumococci. Case report and review. Am J Dis Child. 1979;133(2):187\u2013191.","journal-title":"Am J Dis Child"},{"issue":"16","key":"e_1_3_5_18_1","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1979.03290420033021","article-title":"Meningitis from a pneumococcus moderately resistant to penicillin","volume":"241","author":"Gartner JC","year":"1979","unstructured":"Gartner JC, Michaels RH. Meningitis from a pneumococcus moderately resistant to penicillin. JAMA. 1979 Apr 20;241(16):1707\u20131709.","journal-title":"JAMA"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(77)81339-5"},{"issue":"5","key":"e_1_3_5_20_1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/341978","article-title":"Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae","volume":"35","author":"Lonks JR","year":"2002","unstructured":"Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002;35(5):556\u2013564.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"e_1_3_5_21_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10096-005-0081-z","article-title":"Bacteremic pneumococcal pneumonia associated with macrolide failure","volume":"25","author":"Dylewski J","year":"2006","unstructured":"Dylewski J, Davidson R. Bacteremic pneumococcal pneumonia associated with macrolide failure. Eur J Clin Microbiol Infect Dis. 2006;25(1):39\u201342.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"8","key":"e_1_3_5_22_1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201301-0079OC","article-title":"Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia","volume":"188","author":"Shindo Y","year":"2013","unstructured":"Shindo Y, Ito R, Kobayashi D, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188(8):985\u2013995.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"e_1_3_5_23_1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1473-3099(09)70133-1","article-title":"Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia","volume":"9","author":"Hidron AI","year":"2009","unstructured":"Hidron AI, Low CE, Honig EG, et al. Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis. 2009;9(6):384\u2013392.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"e_1_3_5_24_1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0028-1119809","article-title":"The role of MRSA in healthcare-associated pneumonia","volume":"30","author":"Lam AP","year":"2009","unstructured":"Lam AP, Wunderink RG. The role of MRSA in healthcare-associated pneumonia. Semin Respir Crit Care Med. 2009;30(1):52\u201360.","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"e_1_3_5_25_1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3201\/eid1206.051141","article-title":"Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season","volume":"12","author":"Hageman JC","year":"2006","unstructured":"Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006;12(6):894\u2013899.","journal-title":"Emerg Infect Dis"},{"key":"e_1_3_5_26_1","unstructured":"European Centre for Disease Prevention and Control. 2020 Surveillance of antimicrobial resistance in the European Union (EU)\/European Economic Area (EAA) (EARS-Net). Stockholm:ECDC; 2021 [cited 2021 Dec 19]. Available from: https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx?Dataset=27&HealthTopic=4"},{"issue":"12","key":"e_1_3_5_28_1","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/S1473-3099(16)30267-5","article-title":"GLIMP investigators. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study","volume":"16","author":"Aliberti S","year":"2016","unstructured":"Aliberti S, Reyes LF, Faverio P, et al. GLIMP investigators. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis. 2016;16(12):1364\u20131376.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"e_1_3_5_29_1","first-page":"iii19","article-title":"FOCUS 1: a randomized, double blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File TM","year":"2011","unstructured":"File TM, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl 3):iii19\u2013iii32.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_30_1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson SC","year":"2012","unstructured":"Nicholson SC, Welte T, File TM, et al. A randomised, double blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39:240\u2013246.","journal-title":"Int J Antimicrob Agents"},{"key":"e_1_3_5_31_1","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/cid\/ciz090","article-title":"Efficacy and safety of IV-to-oral lefamulin, a pleuromutilin antibiotic, for treatment of community-acquired bacterial pneumonia: the phase 3 LEAP 1 trial","volume":"69","author":"File TM","year":"2019","unstructured":"File TM, Goldberg L, Das A, et al. Efficacy and safety of IV-to-oral lefamulin, a pleuromutilin antibiotic, for treatment of community-acquired bacterial pneumonia: the phase 3 LEAP 1 trial. Clin Infect Dis. 2019;69:1856\u20131867.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_32_1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"8","author":"Macone AB","year":"2014","unstructured":"Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;8:1127\u20131135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"e_1_3_5_33_1","doi-asserted-by":"crossref","first-page":"ofab135","DOI":"10.1093\/ofid\/ofab135","article-title":"Efficacy of omadacycline versus moxifloxacin in the treatment of community-acquired bacterial pneumonia by disease severity: results from the OPTIC study","volume":"8","author":"Ramirez J","year":"2021","unstructured":"Ramirez J, Deck DH, Eckburg PB, et al. Efficacy of omadacycline versus moxifloxacin in the treatment of community-acquired bacterial pneumonia by disease severity: results from the OPTIC study. Open Forum Infect Dis. 2021;8(6):ofab135.","journal-title":"Open Forum Infect Dis"},{"issue":"15","key":"e_1_3_5_34_1","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1080\/14656566.2021.1957098","article-title":"Delafloxacin as a treatment option for community-acquired pneumonia infection","volume":"22","author":"Nascimento-Carvalho CM","year":"2021","unstructured":"Nascimento-Carvalho CM. Delafloxacin as a treatment option for community-acquired pneumonia infection. Expert Opin Pharmacother. 2021;22(15):1975\u20131982.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"e_1_3_5_35_1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: a novel anionic fluoroquinolone","volume":"73","author":"Mogle BT","year":"2018","unstructured":"Mogle BT, Steele JM, Thomas SJ, et al. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother. 2018 Jun 1;73(6):1439\u20131451.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"e_1_3_5_36_1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/cid\/ciy600","article-title":"Delafloxacin: a new anti-methicillin-resistant staphylococcus aureus fluoroquinolone","volume":"68","author":"Saravolatz LD","year":"2019","unstructured":"Saravolatz LD, Stein GE. Delafloxacin: a new anti-methicillin-resistant staphylococcus aureus fluoroquinolone. Clin Infect Dis. 2019;68(6):1058\u20131062.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"e_1_3_5_37_1","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization","volume":"67","author":"Remy JM","year":"2012","unstructured":"Remy JM, Tow-Keogh CA, McConnell TS, et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother. 2012;67(12):2814\u20132820.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"e_1_3_5_38_1","doi-asserted-by":"crossref","first-page":"e02609","DOI":"10.1128\/AAC.02609-16","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller MA","year":"2017","unstructured":"Pfaller MA, Sader HS, Rhomberg PR, et al., In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017;61(4):e02609\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_39_1","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/AAC.00941-16","article-title":"In vitro activity of delafloxacin tested against isolates of streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis","volume":"60","author":"Flamm RK","year":"2016","unstructured":"Flamm RK, Rhomberg PR, Huband MD, et al. In vitro activity of delafloxacin tested against isolates of streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2016;60:6381\u20136385.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_40_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jac\/dkh304","article-title":"The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae","volume":"54","author":"Hammerschlag MR","year":"2004","unstructured":"Hammerschlag MR, Roblin PM. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae. J Antimicrob Chemother. 2004;54:281\u2013282.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_41_1","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1128\/AAC.47.12.3973-3975.2003","article-title":"Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"47","author":"Waites KB","year":"2003","unstructured":"Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother. 2003;47:3973\u20133975.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"e_1_3_5_42_1","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius AM","year":"2003","unstructured":"Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003;47(10):3260\u20133269.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"e_1_3_5_43_1","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/cid\/ciz787","article-title":"Emergence of delafloxacin-resistant in Staphylococcus aureus in Brooklyn New York","volume":"70","author":"Iregui A","year":"2020","unstructured":"Iregui A, Khan Z, Saquib M, et al. Emergence of delafloxacin-resistant in Staphylococcus aureus in Brooklyn New York. Clin Infect Dis. 2020;70(8):1758\u20131760.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.3.227"},{"issue":"5","key":"e_1_3_5_45_1","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/AAC.02798-15","article-title":"In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae Isolates and selection of gonococcal delafloxacin resistance","volume":"60","author":"Soge OO","year":"2016","unstructured":"Soge OO, Salipante SJ, No D, et al. In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae Isolates and selection of gonococcal delafloxacin resistance. Antimicrob Agents Chemother. 2016;60(5):3106\u20133111.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"e_1_3_5_46_1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/46.5.669","article-title":"Application of fluoroquinolone pharmacodynamics","volume":"46","author":"Wright DH","year":"2000","unstructured":"Wright DH, Brown GH, Peterson ML, et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother. 2000;46(5):669\u2013683.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"e_1_3_5_47_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties","volume":"7","author":"Jorgensen SCJ","year":"2018","unstructured":"Jorgensen SCJ, Mercuro NJ, Davis SL, et al. Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018;7(2):197\u2013217.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"e_1_3_5_48_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijantimicag.2016.08.012","article-title":"Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens","volume":"48","author":"Thabit AK","year":"2016","unstructured":"Thabit AK, Crandon JL, Nicolau DP. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Int J Antimicrob Agents. 2016;48(5):535\u2013541. .","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"e_1_3_5_49_1","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1128\/AAC.00647-16","article-title":"In vivo pharmacodynamic target assessment of delafloxacin against staphylococcus aureus, streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model","volume":"60","author":"Lepak AJ","year":"2016","unstructured":"Lepak AJ, Andes DR. In vivo pharmacodynamic target assessment of delafloxacin against staphylococcus aureus, streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model. Antimicrob Agents Chemother. 2016;60(8):4764\u20134769.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_50_1","volume-title":"Poster session presented at: the ASM Microbe","author":"Bortolon E","year":"2017","unstructured":"Bortolon E, Molstad D, Remy J, et al. In vivo PK\/PD of delafloxacin against Escherichia coli and Pseudomonas aeruginosa in the mouse thigh infection model. Poster session presented at: the ASM Microbe; 2017 Jun 15\u201317; New Orleans, LA, USA."},{"issue":"6","key":"e_1_3_5_51_1","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.00181-13","article-title":"A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms","volume":"57","author":"Bauer J","year":"2013","unstructured":"Bauer J, Siala W, Tulkens PM, et al. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother. 2013;57(6):2726\u20132737.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"e_1_3_5_52_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire S","year":"2011","unstructured":"Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011 Feb;55(2):649\u2013658.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_53_1","volume-title":"Poster presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases","author":"Ding Y","year":"2011","unstructured":"Ding Y, Villet RA, Lee JC, et al. Treatment of renal abscesses caused by Staphylococcus aureus MW2, using delafloxacin and moxifloxacin. Poster presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases; 2011 May 7\u201310; Milan, Italy."},{"issue":"1","key":"e_1_3_5_54_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2015.11.019","article-title":"Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers","volume":"38","author":"Hoover R","year":"2016","unstructured":"Hoover R, Hunt T, Benedict M, et al., Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers. Clin Ther. 2016;38(1):53\u201365.","journal-title":"Clin Ther"},{"issue":"1","key":"e_1_3_5_55_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clinthera.2015.10.016","article-title":"Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age","volume":"38","author":"Hoover R","year":"2016","unstructured":"Hoover R, Hunt T, Benedict M, et al., Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age. Clin Ther. 2016;38(1):39\u201352.","journal-title":"Clin Ther"},{"key":"e_1_3_5_56_1","volume-title":"Melinta therapeutics, inc. division of anti-infective products","author":"Wu K","year":"2017","unstructured":"Wu K, Yan Z. Clinical pharmacology and biopharmaceutical review. Delafloxacin. NDA#208610, 208611. In: Melinta therapeutics, inc. division of anti-infective products. Center for Drug Evaluation and Research. US Food and Drug Administration; 2017."},{"issue":"4","key":"e_1_3_5_57_1","first-page":"245","article-title":"Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone","volume":"25","author":"Parra-Ruiz J","year":"2012","unstructured":"Parra-Ruiz J, Hern\u00e1ndez-Quero J. Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone. Rev Esp Quimioter. 2012;25(4):245\u2013251.","journal-title":"Rev Esp Quimioter"},{"key":"e_1_3_5_58_1","unstructured":"Baxdela (delafloxacin) [Package Insert]. Lincolnshire IL: Melinta Therapeutics Inc; 2017 [cited 2021 Dec 11]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208610s000 208611s000lbl.pdf"},{"issue":"12","key":"e_1_3_5_59_1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3109\/00498254.2015.1042946","article-title":"Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration","volume":"45","author":"McEwen A","year":"2015","unstructured":"McEwen A, Lawrence L, Hoover R, et al., Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration. Xenobiotica. 2015;45(12):1054\u20131062.","journal-title":"Xenobiotica"},{"key":"e_1_3_5_60_1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.clinthera.2017.04.009","article-title":"The pharmacokinetics of the CYP3A substrate midazolam after steady-state dosing of delafloxacin","volume":"39","author":"Paulson SK","year":"2017","unstructured":"Paulson SK, Wood-Horrall RN, Hoover R, et al. The pharmacokinetics of the CYP3A substrate midazolam after steady-state dosing of delafloxacin. Clin Ther. 2017;39:1182\u20131190.","journal-title":"Clin Ther"},{"key":"e_1_3_5_61_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jcph.817","article-title":"Clinical pharmacology of delafloxacin in patients with hepatic impairment","volume":"57","author":"Hoover R","year":"2017","unstructured":"Hoover R, Marbury TC, Preston RA, et al. Clinical pharmacology of delafloxacin in patients with hepatic impairment. J Clin Pharmacol. 2017;57:328\u2013335.","journal-title":"J Clin Pharmacol"},{"key":"e_1_3_5_62_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/jcph.1041","article-title":"Delafloxacin pharmacokinetics in subjects with varying degrees of renal function","volume":"58","author":"Hoover R","year":"2018","unstructured":"Hoover R, H A Jr, Lawrence L, et al. Delafloxacin pharmacokinetics in subjects with varying degrees of renal function. J Clin Pharm. 2018;58:514\u2013521.","journal-title":"J Clin Pharm"},{"issue":"7","key":"e_1_3_5_63_1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jcph.1099","article-title":"Pharmacokinetics of intravenous delafloxacin in patients with end-stage renal disease","volume":"58","author":"Hoover R","year":"2018","unstructured":"Hoover R, H A Jr, Lawrence L, et al. Pharmacokinetics of intravenous delafloxacin in patients with end-stage renal disease. J Clin Pharmacol. 2018;58(7):913\u2013919.","journal-title":"J Clin Pharmacol"},{"key":"e_1_3_5_64_1","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1128\/AAC.04813-14","article-title":"A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization","volume":"59","author":"Litwin JS","year":"2015","unstructured":"Litwin JS, Benedict MS, Thorn MD, et al. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother. 2015;59:3469\u20133473.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"e_1_3_5_65_1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1039\/c8pp00019k","article-title":"Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin","volume":"17","author":"Ferguson J DRS","year":"2018","unstructured":"Ferguson J DRS, Ibbotson S, Ibbotson S, et al. Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin. Photochem Photobiol Sci. 2018;17(6):773\u2013780.","journal-title":"Photochem Photobiol Sci"},{"key":"e_1_3_5_66_1","unstructured":"Longcor J Hopkins S Wikler M et al. A phase 2 safety and efficacy study of oral delafloxacin in subjects with acute bacterial exacerbation of chronic bronchitis (ABECB). Presented at: ID Week; San Diego CA; 2012 Oct 17\u201321 [cited 2021 Dec 12]; Available from: https:\/\/idsa.confex.com\/idsa\/2012\/webprogram\/Paper37662"},{"issue":"1","key":"e_1_3_5_67_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/crj.13262","article-title":"Delafloxacin\u2013A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"15","author":"Millar BC","year":"2021","unstructured":"Millar BC, McCaughan J, Rendall JC, et al. Delafloxacin\u2013A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis. Clin Respir J. 2021 Jan;15(1):116\u2013120.","journal-title":"Clin Respir J"},{"key":"e_1_3_5_68_1","unstructured":"Longcor J Hopkins S Wikler M et al. A phase 2 study of the safety and efficacy of oral delafloxacin (DLX) in community acquired pneumonia (CAP). Presented at: ID Week; San Diego CA; 2012 Oct 17\u201321 [cited 2021 Dec 12]. Available from: https:\/\/idsa.confex.com\/idsa\/2012\/webprogram\/Paper37662"},{"key":"e_1_3_5_69_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","article-title":"A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections","volume":"30","author":"O\u2019Riordan W","year":"2015","unstructured":"O\u2019Riordan W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015;30:67\u201373.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"e_1_3_5_70_1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jac\/dkv411","article-title":"A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin","volume":"71","author":"Kingsley J","year":"2016","unstructured":"Kingsley J, Mehra P, Lawrence LE, et al. A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016;71(3):821\u2013829.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"e_1_3_5_71_1","doi-asserted-by":"crossref","first-page":"ofz514","DOI":"10.1093\/ofid\/ofz514","article-title":"A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada JP","year":"2019","unstructured":"Horcajada JP, Salata RA, \u00c1lvarez-Sala R, et al., A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Open Forum Infect Dis. 2019;7(1):ofz514.","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_5_72_1","doi-asserted-by":"crossref","first-page":"e01949","DOI":"10.1128\/AAC.01949-19","article-title":"Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial","volume":"64","author":"McCurdy S","year":"2020","unstructured":"McCurdy S, Keedy K, Lawrence L, et al. Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial. Antimicrob Agents Chemother. 2020;64:e01949\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_73_1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijid.2020.06.018","article-title":"Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the delafloxacin phase 3 CABP trial","volume":"97","author":"McCurdy S","year":"2020","unstructured":"McCurdy S, Nenninger A, Sheets A, et al. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the delafloxacin phase 3 CABP trial. Int J Infect Dis. 2020;97:374.","journal-title":"Int J Infect Dis"},{"key":"e_1_3_5_74_1","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study","volume":"72","author":"Pullman J","year":"2017","unstructured":"Pullman J, Gardovskis J, Farley B, PROCEED Study Group, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72:3471\u20133480.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"e_1_3_5_75_1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study","volume":"67","author":"O\u2019Riordan W","year":"2018","unstructured":"O\u2019Riordan W, McManus A, Teras J, PROCEED Study Group, et al. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018;675:657\u2013666.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"e_1_3_5_76_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/OLQ.0000000000000971","article-title":"Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, noninferiority, phase 3, multicenter, randomized study","volume":"46","author":"Hook EW","year":"2019","unstructured":"Hook EW, Golden MR, Taylor SN, et al. Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, noninferiority, phase 3, multicenter, randomized study. Sex Transm Dis. 2019 May;46(5):279\u2013286.","journal-title":"Sex Transm Dis"},{"issue":"10","key":"e_1_3_5_77_1","doi-asserted-by":"crossref","first-page":"ofy220","DOI":"10.1093\/ofid\/ofy220","article-title":"Safety of delafloxacin: focus on adverse events of special interest","volume":"5","author":"Lodise T","year":"2018","unstructured":"Lodise T, Corey R, Hooper D, et al., Safety of delafloxacin: focus on adverse events of special interest. Open Forum Infect Dis. 2018;5(10): ofy220.","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_5_78_1","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/jamainternmed.2015.5389","article-title":"Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone","volume":"175","author":"Lee CC","year":"2015","unstructured":"Lee CC, Lee MT, Chen YS, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015;175:1839\u20131847.","journal-title":"JAMA Intern Med"},{"key":"e_1_3_5_79_1","unstructured":"U.S. Food and Drug Administration. Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 2018 Dec 20 [cited 2021 Dec 12]. Available from: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm628753.htm.opens\/in\/new\/tab"},{"key":"e_1_3_5_80_1","doi-asserted-by":"crossref","first-page":"k678","DOI":"10.1136\/bmj.k678","article-title":"Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study","volume":"360","author":"Pasternak B","year":"2018","unstructured":"Pasternak B, Inghammar M, Svanstr\u00f6m H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678.","journal-title":"BMJ"},{"key":"e_1_3_5_81_1","unstructured":"European Medicines Agency. Fluoroquinolone and quinolone antibiotics: PRAC recommends restrictions on use (Europa.eu) New restrictions follow review of disabling and potentially long-lasting side effects. EMA\/668915\/2018; 2018 Oct 5 [cited 2021 Dec 12]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/fluoroquinolone-quinolone-antibiotics-prac-recommends-restrictions-use_en.pdf"},{"key":"e_1_3_5_82_1","unstructured":"European Medicines Agency. Summary of risk management plan for quofenix (delafloxacin).[cited 2021 Dec 12]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/quofenix-epar-risk-management-plan-summary_pdf"},{"key":"e_1_3_5_83_1","unstructured":"Melinta Therapeutics Announces U.S. FDA Approval of supplemental new drug application for BAXDELA\u00ae (delafloxacin) for the treatment of community-acquired bacterial pneumonia (CABP). Melinta Therapeutics Inc; 2019 [cited 2021 Dec 12]. Available from: http:\/\/ir.melinta.com\/news-releases\/news-release-details\/melinta-therapeutics-announces-us-fda-approval-supplemental-news"},{"key":"e_1_3_5_84_1","unstructured":"European Medicines Agency. EMEA-001080-PIP01-10 | European Medicines Agency. (europa.eu); [cited 2021 Dec 19]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-quofenix_en-0.pdf"},{"key":"e_1_3_5_85_1","unstructured":"European Medicines Agency. EMA\/CHMP\/99783\/2021. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (postauthorisation). 2021 [cited 2021 Dec 19]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-quofenix-ii-03_en.pdf"},{"key":"e_1_3_5_86_1","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/j.ijid.2012.01.003","article-title":"Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza","volume":"16","author":"Metersky ML","year":"2012","unstructured":"Metersky ML, Masterton RG, Lode H, et al. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012;16:e321\u201331.","journal-title":"Int J Infect Dis"}],"updated-by":[{"DOI":"10.1080\/17512433.2024.2402165","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000}}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2022.2100346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T06:04:01Z","timestamp":1725861841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2022.2100346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,3]]}},"alternative-id":["10.1080\/17512433.2022.2100346"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2022.2100346","relation":{"correction":[{"id-type":"doi","id":"10.1080\/17512433.2024.2402165","asserted-by":"object"}]},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}